Ilika plc Q&A with Dr Tom McColm at Baden Hill (LON:IKA)

Ilika Plc

Ilika plc (LON:IKA) is the topic of conversation when Baden Hill’s Partner and Equity Specialist Dr Tom McColm caught up with DirectorsTalk for an exclusive interview.

Q1: We’ve just seen that Ilika has published final results which were looking pretty good, where do you see the company’s first OEM licencing deal coming from?

A1: Yes, it’s a good question, it’s the thing that everyone’s looking for. I actually think it’ll be from one of the more specialised small scale Stereax applications and even though it was their latest and most recent product launch, the M50, this very very small millimetre scale device.

I think it will come for that product in the medical device application area because it’s such a high value add and there isn’t really any other batteries that can perform those sort of functions.

So, if I was a betting man, I’d say it’ll be an M50 application and what it definitely won’t be will be the big goliath cells in EV, I think that’s still a long way off.

Q2: So, what should investors be looking out for news flow wise over the next 12 months?

A2: Obviously, the one that I mentioned earlier, is we’re looking for this first big OEM licencing deal, it does seem like they’re getting closer and closer in a number of areas so that one will be a bit of a game changer.

Also, an important area is the relationship that they have with Semefab on the manufacturing side, information on that will be interesting, how that’s going, how that scale-up’s going because without that, the whole business model won’t work.

So, big first OEM licencing deal and good progress on the manufacturing partnership with Semefab.

Q3: Finally, what’s your view on the overall global battery market going forward?

A3: I think it’s just going to absolutely going to get massive. There’s two huge global megatrends at the moment, you’ve got the decarbonisation of energy and you’ve got the electrification of transport, both of those require vast amounts of storage.

Alongside that, you’ve still got the usual markets, consumer electronics markets, mobile phones etc. so I think there’s going to be a huge growth in the volume of batteries produced over the next 10/20 years.

Ilika plc is a pioneer in solid state battery technology. Ilika’s Stereax® state batteries include miniaturised products for powering wireless sensors in applications ranging from hostile industrial environments to medical implants.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika plc Advances Solid-State Batteries With 10Ah Goliath Breakthrough (Video)

Ilika plc has shipped its 10Ah Goliath solid-state battery prototypes, marking a major scale-up from earlier designs. CEO Graeme Purdy outlines how higher-energy materials and an automated pilot line delivered a 93% yield, signalling readiness for larger-scale manufacturing.

Ilika ships new 10Ah solid state battery prototypes as automation boosts output

Ilika has started delivering its 10Ah Goliath solid state battery prototypes, offering five times the capacity of earlier versions and manufactured on its new automated pilot line.

Ilika: Building a bridge from niche batteries to mass market demand

Ilika is translating niche micro-battery expertise into a larger bet on scalable solid-state solutions for EVs and energy storage.

Ilika targets neuromodulation market with medical battery offering

Ilika is stepping directly into the medical-device market with its solid-state microbattery platform now featured at NANS 2026.

Ilika’s pack design shifts focus from cells to architecture

Ilika’s solid-state cells allowed a full battery pack redesign, cutting 100 kg, lowering cost, and extending range, without compromising safety.

Ilika CEO on Stereax production, Goliath progress, and growing market demand

Ilika's Graeme Purdy shares updates on the company’s advancements in solid-state battery technology, including Stereax manufacturing milestones, the upcoming release of Goliath P1.5 prototypes, and expanding customer interest across medical and industrial sectors.

Search

Search